Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
77.6M
-
Shares change
-
+1.81M
-
Total reported value, excl. options
-
$3.13B
-
Value change
-
+$92.1M
-
Put/Call ratio
-
0.16
-
Number of buys
-
87
-
Number of sells
-
-75
-
Price
-
$40.28
Significant Holders of CG Oncology, Inc. - Common Stock (CGON) as of Q3 2025
203 filings reported holding CGON - CG Oncology, Inc. - Common Stock as of Q3 2025.
CG Oncology, Inc. - Common Stock (CGON) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77.6M shares
.
Largest 10 shareholders include VANGUARD GROUP INC (6.58M shares), Decheng Capital LLC (6.37M shares), WELLINGTON MANAGEMENT GROUP LLP (5.51M shares), BlackRock, Inc. (4.59M shares), FMR LLC (3.87M shares), TCG Crossover Management, LLC (3.67M shares), BRAIDWELL LP (3.28M shares), Foresite Capital Management VI LLC (2.22M shares), ALLIANCEBERNSTEIN L.P. (2.14M shares), and UBS Group AG (2.13M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.